Ovarian cancer, Secondary cancers
Results
Phase 2
This trial looked at adding a drug called cediranib to paclitaxel chemotherapy for ovarian cancer. The aim was to reduce the risk of developing a blockage in the bowel. This can happen if a cancer spreads from the ovary.
It was for women whose ovarian cancer had come back or continued to grow after . The trial included women who had:
epithelial ovarian cancer
fallopian tube cancer
primary peritoneal cancer
Doctors treat these cancers in the same way. So, when we use the term ovarian cancer in this summary, we are referring to all 3.
The trial was open for people to join between 2018 and 2021. The team published the results in 2024.
Recruitment start: 10 April 2018
Recruitment end: 15 February 2021
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Gordon Jayson
AstraZeneca
Centre for Trials Research (Cardiff University)
University of Manchester
Last reviewed: 7 July 2025
CRUK internal database number: 15322
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
